Johnson & Johnson will not be allowed to pursue an interlocutory appeal of the Court's pre-emption decision, which allows Tylenol autism lawsuits to move forward over adequacy of the acetaminophen pregnancy warnings
Judge presiding over all Tylenol autism lawsuits invited the FDA to give their opinion on proposed pregnancy warnings for acetaminophen drugs.
Trial judge determined last month that Tylenol autism and ADHD lawsuits are not preempted by federal law, and the drug maker seeks an immediate appeal of the decision before the litigation moves forward.
The ruling means that Tylenol lawsuits over the failure to warn about the risk of autism and ADHD lawsuits can move forward in the federal court system
Plaintiffs say the invitation is unnecessary, saying their cases should not depend on proposed acetaminophen pregnancy warnings submitted earlier this month.
Federal judge presiding over lawsuits brought by families nationwide asked plaintiffs' lawyers to propose Tylenol pregnancy warnings that should have been added to the painkiller acetaminophen
Plaintiffs will have 60 days to fill out a Fact Sheet, which will help streamline the process of gathering information about each of the Tylenol injury claims.
The lawsuits claim children developed ADHD and autism from Tylenol use by the mother which occurred during pregnancy.
The Tylenol autism and ADHD lawsuits claim the manufacturers failed to adequately warn pregnant women of the risks of taking acetaminophen during pregnancy.
Lawsuit alleges pharmacies failed to warn pregnant women about the risk of developmental disorders and ADHD from acetaminophen, the active ingredient in Tylenol
